Clinical Trial

Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Summary
This study will evaluate long-term safety and tolerability of valbenazine in participants with chorea associated with Huntington Disease (HD) who participated in Study NBI-98854-HD3006 (NCT04400331) in Canada.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-04 -> 2028-04 2026-06-19
minor Completion pushed: 2026-04 -> 2028-04 2026-06-19
Trial Details
NCT Number NCT06312189
Lead Sponsor Neurocrine Biosciences
Conditions Chorea, Huntington
Enrollment 7 participants
Start Date 2024-04-24
Primary Completion 2028-04 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-06-18